Celera Corporation

Steve Ruben

Tao He

Candy Lee

Bruno Domon

Charles E Birse

Paul A Moore

Elizabeth Joseloff

Mehdi Mesri

Marcia Lewis

Karen Van Orden

Sudeepta Aggarwal

Yeounjin Kim

Yeoun Jin Kim

Dong Fang

Ian McCaffery

Aiqun Li

Jenny Heidbrink

Yeoun Jim Kim

Charles Birse

Marica Lewis

Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Methods and compositions for diagnosing and treating diseases

Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

Lung cancer markers and uses thereof

Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.

Methods and compositions for treating and diagnosing diseases

Lung cancer markers, and uses thereof

Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets ('CAT'). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Cancer targets and uses thereof

Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of Maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of Maba, and methods for screening agents that modulate the Maba level or activity in vivo or in vitro.

Methods and compositions for treating diseases targeting maba

The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.

Detection of CXADR protein for diagnosis of kidney cancer

Growing community of inventors

Brookeville, MD, United States of America

Steve Ruben